Is INTT or CTKB more profitable?

inTEST has a net margin of 2.33% compared to Cytek Biosciences' net margin of -36.25%. inTEST's return on equity of 5.31% beat Cytek Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets inTEST 2.33% 5.31% 3.42% Cytek Biosciences -36.25% -10.07% -7.56%

Do analysts recommend INTT or OPTX?

inTEST presently has a consensus target price of $19.00, suggesting a potential upside of 9.20%. Given inTEST's stronger consensus rating and higher possible upside, equities research analysts plainly believe inTEST is more favorable than Syntec Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score inTEST 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Syntec Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, INTT or OPTX?

inTEST has higher revenue and earnings than Syntec Optics. Syntec Optics is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio inTEST $121.07M 1.81 $9.34M $0.04 435.00 Syntec Optics $28.08M 19.01 -$1.79M -$0.08 N/A

Is INTT or OPTX more profitable?

inTEST has a net margin of 2.33% compared to Syntec Optics' net margin of -10.95%. inTEST's return on equity of 5.31% beat Syntec Optics' return on equity. Company Net Margins Return on Equity Return on Assets inTEST 2.33% 5.31% 3.42% Syntec Optics -10.95% -30.86% -12.35%

Which has better valuation and earnings, PRE or INTT?

inTEST has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prenetics Global $92.39M 3.95 -$37.71M -$4.58 N/A inTEST $121.07M 1.81 $9.34M $0.04 435.00

Is PRE or INTT more profitable?

inTEST has a net margin of 2.33% compared to Prenetics Global's net margin of -62.45%. inTEST's return on equity of 5.31% beat Prenetics Global's return on equity. Company Net Margins Return on Equity Return on Assets Prenetics Global -62.45% -20.33% -15.42% inTEST 2.33% 5.31% 3.42%

Which has higher earnings & valuation, LAB or INTT?

inTEST has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Standard BioTools $85.33M 4.06 -$74.90M $0.20 4.44 inTEST $121.07M 1.81 $9.34M $0.04 435.00

inTEST (INTT) Competitors

$17.40 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$17.38 -0.02 (-0.14%)

As of 06/12/2026 07:36 PM Eastern

Compare

INTT vs. FEIM, CTKB, OPTX, PRE, and LAB

Should you buy inTEST stock or one of its competitors? MarketBeat compares inTEST with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with inTEST include Frequency Electronics (FEIM), Cytek Biosciences (CTKB), Syntec Optics (OPTX), Prenetics Global (PRE), and Standard BioTools (LAB). These companies are all part of the "measuring and control equipment" industry.

How does inTEST compare to Frequency Electronics?

Frequency Electronics (NASDAQ:FEIM) and inTEST (NYSE:INTT) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

58.6% of Frequency Electronics shares are owned by institutional investors. Comparatively, 63.2% of inTEST shares are owned by institutional investors. 28.0% of Frequency Electronics shares are owned by insiders. Comparatively, 5.2% of inTEST shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Frequency Electronics had 4 more articles in the media than inTEST. MarketBeat recorded 4 mentions for Frequency Electronics and 0 mentions for inTEST. Frequency Electronics' average media sentiment score of 0.81 beat inTEST's score of 0.00 indicating that Frequency Electronics is being referred to more favorably in the media.

Company	Overall Sentiment
Frequency Electronics	Positive
inTEST	Neutral

Frequency Electronics has higher earnings, but lower revenue than inTEST. Frequency Electronics is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Frequency Electronics	$69.81M	10.61	$23.69M	$0.75	100.37
inTEST	$121.07M	1.81	$9.34M	$0.04	435.00

Frequency Electronics has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, inTEST has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Frequency Electronics has a net margin of 10.78% compared to inTEST's net margin of 2.33%. Frequency Electronics' return on equity of 12.69% beat inTEST's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Frequency Electronics	10.78%	12.69%	7.84%
inTEST	2.33%	5.31%	3.42%

Frequency Electronics currently has a consensus target price of $43.67, suggesting a potential downside of 41.99%. inTEST has a consensus target price of $19.00, suggesting a potential upside of 9.20%. Given inTEST's higher probable upside, analysts plainly believe inTEST is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
inTEST	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Frequency Electronics beats inTEST on 12 of the 16 factors compared between the two stocks.

How does inTEST compare to Cytek Biosciences?

inTEST (NYSE:INTT) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

inTEST presently has a consensus target price of $19.00, suggesting a potential upside of 9.20%. Cytek Biosciences has a consensus target price of $5.69, suggesting a potential upside of 43.62%. Given Cytek Biosciences' higher probable upside, analysts plainly believe Cytek Biosciences is more favorable than inTEST.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
inTEST	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

inTEST has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
inTEST	$121.07M	1.81	$9.34M	$0.04	435.00
Cytek Biosciences	$204.17M	2.50	-$66.54M	-$0.57	N/A

In the previous week, Cytek Biosciences had 3 more articles in the media than inTEST. MarketBeat recorded 3 mentions for Cytek Biosciences and 0 mentions for inTEST. Cytek Biosciences' average media sentiment score of 0.62 beat inTEST's score of 0.00 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
inTEST	Neutral
Cytek Biosciences	Positive

inTEST has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

63.2% of inTEST shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 5.2% of inTEST shares are owned by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

inTEST has a net margin of 2.33% compared to Cytek Biosciences' net margin of -36.25%. inTEST's return on equity of 5.31% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
inTEST	2.33%	5.31%	3.42%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Summary

inTEST and Cytek Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does inTEST compare to Syntec Optics?

inTEST (NYSE:INTT) and Syntec Optics (NASDAQ:OPTX) are both small-cap measuring and control equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

inTEST has a net margin of 2.33% compared to Syntec Optics' net margin of -10.95%. inTEST's return on equity of 5.31% beat Syntec Optics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
inTEST	2.33%	5.31%	3.42%
Syntec Optics	-10.95%	-30.86%	-12.35%

inTEST presently has a consensus target price of $19.00, suggesting a potential upside of 9.20%. Given inTEST's stronger consensus rating and higher possible upside, equities research analysts plainly believe inTEST is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
inTEST	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

63.2% of inTEST shares are held by institutional investors. 5.2% of inTEST shares are held by company insiders. Comparatively, 0.8% of Syntec Optics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

inTEST has higher revenue and earnings than Syntec Optics. Syntec Optics is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
inTEST	$121.07M	1.81	$9.34M	$0.04	435.00
Syntec Optics	$28.08M	19.01	-$1.79M	-$0.08	N/A

In the previous week, Syntec Optics had 6 more articles in the media than inTEST. MarketBeat recorded 6 mentions for Syntec Optics and 0 mentions for inTEST. Syntec Optics' average media sentiment score of 0.19 beat inTEST's score of 0.00 indicating that Syntec Optics is being referred to more favorably in the news media.

Company	Overall Sentiment
inTEST	Neutral
Syntec Optics	Neutral

inTEST has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Syntec Optics has a beta of -0.82, meaning that its stock price is 182% less volatile than the broader market.

Summary

inTEST beats Syntec Optics on 13 of the 16 factors compared between the two stocks.

How does inTEST compare to Prenetics Global?

Prenetics Global (NASDAQ:PRE) and inTEST (NYSE:INTT) are both small-cap measuring and control equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Prenetics Global has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, inTEST has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

inTEST has a net margin of 2.33% compared to Prenetics Global's net margin of -62.45%. inTEST's return on equity of 5.31% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prenetics Global	-62.45%	-20.33%	-15.42%
inTEST	2.33%	5.31%	3.42%

inTEST has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prenetics Global	$92.39M	3.95	-$37.71M	-$4.58	N/A
inTEST	$121.07M	1.81	$9.34M	$0.04	435.00

Prenetics Global presently has a consensus price target of $32.33, indicating a potential upside of 49.48%. inTEST has a consensus price target of $19.00, indicating a potential upside of 9.20%. Given Prenetics Global's higher probable upside, analysts clearly believe Prenetics Global is more favorable than inTEST.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
inTEST	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 63.2% of inTEST shares are held by institutional investors. 5.2% of inTEST shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Prenetics Global had 15 more articles in the media than inTEST. MarketBeat recorded 15 mentions for Prenetics Global and 0 mentions for inTEST. Prenetics Global's average media sentiment score of 0.61 beat inTEST's score of 0.00 indicating that Prenetics Global is being referred to more favorably in the media.

Company	Overall Sentiment
Prenetics Global	Positive
inTEST	Neutral

Summary

inTEST beats Prenetics Global on 10 of the 15 factors compared between the two stocks.

How does inTEST compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and inTEST (NYSE:INTT) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Standard BioTools currently has a consensus target price of $1.35, indicating a potential upside of 52.08%. inTEST has a consensus target price of $19.00, indicating a potential upside of 9.20%. Given Standard BioTools' higher probable upside, equities analysts plainly believe Standard BioTools is more favorable than inTEST.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
inTEST	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Standard BioTools has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, inTEST has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

In the previous week, Standard BioTools had 6 more articles in the media than inTEST. MarketBeat recorded 6 mentions for Standard BioTools and 0 mentions for inTEST. Standard BioTools' average media sentiment score of 0.39 beat inTEST's score of 0.00 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Overall Sentiment
Standard BioTools	Neutral
inTEST	Neutral

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 63.2% of inTEST shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by company insiders. Comparatively, 5.2% of inTEST shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Standard BioTools has a net margin of 73.46% compared to inTEST's net margin of 2.33%. inTEST's return on equity of 5.31% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	73.46%	-8.18%	-6.43%
inTEST	2.33%	5.31%	3.42%

inTEST has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than inTEST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	4.06	-$74.90M	$0.20	4.44
inTEST	$121.07M	1.81	$9.34M	$0.04	435.00

Summary

inTEST beats Standard BioTools on 9 of the 16 factors compared between the two stocks.

Get inTEST News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INTT vs. The Competition

Export

Metric	inTEST	Instruments to measure electricity Industry	Computer Sector	NYSE Exchange
Market Cap	$218.63M	$109.35M	$38.78B	$23.31B
Dividend Yield	N/A	N/A	3.16%	4.05%
P/E Ratio	75.66	75.66	80.73	31.31
Price / Sales	1.81	0.90	633.06	100.04
Price / Cash	5.75	5.75	49.02	18.65
Price / Book	2.20	2.20	9.81	4.69
Net Income	$9.34M	-$2.88M	$1.07B	$1.08B
7 Day Performance	11.32%	11.32%	0.04%	2.07%
1 Month Performance	-5.64%	-5.64%	5.87%	3.44%
1 Year Performance	154.76%	154.76%	160.30%	24.11%

inTEST Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INTT inTEST	0.9659 of 5 stars	$17.40 flat	$19.00 +9.2%	+154.8%	$218.63M	$121.07M	75.66	320	Gap Down
FEIM Frequency Electronics	1.5455 of 5 stars	$66.94 -4.3%	$43.67 -34.8%	+308.5%	$688.54M	$69.81M	89.25	200	Gap Up
CTKB Cytek Biosciences	2.2992 of 5 stars	$4.13 +2.2%	$5.69 +37.7%	+23.0%	$521.74M	$201.49M	N/A	500
OPTX Syntec Optics	0.1724 of 5 stars	$11.63 -2.4%	N/A	+867.2%	$479.73M	$28.08M	N/A	3	Analyst Downgrade Short Interest Increase Gap Up
PRE Prenetics Global	2.3768 of 5 stars	$20.93 +4.7%	$32.33 +54.5%	+208.6%	$337.48M	$92.39M	N/A	1	Trending News Earnings Report Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:INTT) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

inTEST (INTT) Competitors

INTT vs. FEIM, CTKB, OPTX, PRE, and LAB

How does inTEST compare to Frequency Electronics?

Summary

How does inTEST compare to Cytek Biosciences?

Summary

How does inTEST compare to Syntec Optics?

Summary

How does inTEST compare to Prenetics Global?

Summary

How does inTEST compare to Standard BioTools?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTT vs. The Competition

inTEST Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

inTEST (INTT) Competitors

INTT vs. FEIM, CTKB, OPTX, PRE, and LAB

How does inTEST compare to Frequency Electronics?

Do insiders & institutionals hold more shares of FEIM or INTT?

Does the media favor FEIM or INTT?

Which has stronger valuation and earnings, FEIM or INTT?

Which has more risk & volatility, FEIM or INTT?

Is FEIM or INTT more profitable?

Do analysts prefer FEIM or INTT?

Summary

How does inTEST compare to Cytek Biosciences?

Do analysts rate INTT or CTKB?

Which has better earnings & valuation, INTT or CTKB?

Does the media favor INTT or CTKB?

Which has more risk and volatility, INTT or CTKB?

Do insiders and institutionals hold more shares of INTT or CTKB?

Is INTT or CTKB more profitable?

Summary

How does inTEST compare to Syntec Optics?

Is INTT or OPTX more profitable?

Do analysts recommend INTT or OPTX?

Do institutionals & insiders hold more shares of INTT or OPTX?

Which has preferable earnings & valuation, INTT or OPTX?

Does the media refer more to INTT or OPTX?

Which has more volatility & risk, INTT or OPTX?

Summary

How does inTEST compare to Prenetics Global?

Which has more risk & volatility, PRE or INTT?

Is PRE or INTT more profitable?

Which has better valuation and earnings, PRE or INTT?

Do analysts rate PRE or INTT?

Do institutionals and insiders believe in PRE or INTT?

Does the media prefer PRE or INTT?

Summary

How does inTEST compare to Standard BioTools?

Do analysts rate LAB or INTT?

Which has more risk and volatility, LAB or INTT?

Does the media prefer LAB or INTT?

Do insiders and institutionals believe in LAB or INTT?

Is LAB or INTT more profitable?

Which has higher earnings & valuation, LAB or INTT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTT vs. The Competition

inTEST Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools